What Are the Types of HSCT? Autologous vs Allogeneic Transplant
Overview: The two main types of hematopoietic stem cell transplantation are autologous HSCT and allogeneic HSCT. Autologous HSCT uses the patient’s own stem cells. Allogeneic HSCT uses stem cells from a healthy donor.
Autologous HSCT is commonly used for some lymphomas and multiple myeloma. Allogeneic HSCT can rebuild blood production and may also allow donor immune cells to attack cancer. It is often considered for selected high-risk blood cancers. The best approach depends on the disease, risk level, treatment goals, and the patient’s health.
What is autologous HSCT?
In autologous HSCT, the patient’s own stem cells are collected and stored before intensive treatment. After high-dose treatment, the stored cells are infused back into the patient to help blood production recover.
The usual steps are stem cell mobilization, collection through an apheresis machine, freezing and storage, high-dose treatment, and reinfusion of the stored cells.
Which diseases may be treated with autologous HSCT?
Lymphoma: Autologous HSCT may be used for some patients with a high risk of relapse, for relapsed disease, or as consolidation after a good response to treatment. The decision depends on lymphoma type and stage, previous treatment, response, and overall health.
Multiple myeloma: Autologous HSCT is an important part of treatment for some eligible patients. The team assesses age, health, organ function, and disease control.
Other blood diseases: In selected situations, autologous HSCT may also be considered for other conditions.
What is allogeneic HSCT?
Allogeneic HSCT uses stem cells from a healthy donor to replace or rebuild the patient’s abnormal blood-forming and immune systems. The donor may be a matched sibling, an unrelated volunteer, a haploidentical family member, or a cord blood unit.
How can allogeneic HSCT treat blood cancer?
In addition to restoring blood production, donor immune cells may recognize and attack cancer cells that remain after treatment. This is called the graft-versus-leukemia (GVL) effect or, more broadly, the graft-versus-tumor (GVT) effect. This immune effect is an important reason that allogeneic HSCT may help some patients with high-risk leukemia and other blood cancers.
Who may need allogeneic HSCT?
Allogeneic HSCT may be considered for selected patients with high-risk acute myeloid leukemia (AML), high-risk acute lymphoblastic leukemia (ALL), relapsed or treatment-resistant leukemia, high-risk myelodysplastic syndromes (MDS), severe aplastic anemia, and some inherited blood disorders.
How do autologous and allogeneic HSCT differ?
Autologous HSCT uses the patient’s own cells and does not require a donor. It usually does not provide a donor immune effect and has a lower risk of donor-related immune complications. Common uses include selected lymphomas and multiple myeloma.
Allogeneic HSCT uses cells from a healthy donor and requires donor matching. It may provide a graft-versus-tumor effect, but it also carries risks such as graft-versus-host disease (GVHD). It is often used for leukemia, high-risk MDS, and selected other conditions.
Where can the stem cells come from?
Peripheral blood: Widely used. Collection is well established, and blood count recovery may be relatively fast.
Bone marrow: A traditional source collected directly from the bone marrow.
Cord blood: Collected from a newborn’s umbilical cord and placenta. It can be used as a stem cell source for selected patients.
How is the transplant type chosen?
Neither type is simply “better” or “safer” for every patient. The choice depends on the disease, treatment goal, risk of relapse, age, general health, and expected transplant risks. Autologous HSCT may be more suitable for some patients with lymphoma or multiple myeloma, while allogeneic HSCT may offer more benefit for some high-risk leukemias. The transplant team makes an individualized recommendation.
Summary
Autologous HSCT uses the patient’s own stem cells and is often used for selected lymphomas and multiple myeloma. Allogeneic HSCT uses donor cells, can rebuild blood and immune function, and may provide an immune effect against cancer. The right choice depends on the disease and the individual patient.